Bristol Myers Squibb

Bristol Myers Squibb Announces Dividend

Retrieved on: 
Friday, March 1, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Bristol Myers Squibb, BMY, Holding company

Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents ($0.60) per share on the $0.10 par value common stock of the company.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents ($0.60) per share on the $0.10 par value common stock of the company.
  • The dividend is payable on May 1, 2024, to stockholders of record at the close of business on April 5, 2024.
  • In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company’s $2.00 convertible preferred stock, payable on June 3, 2024, to stockholders of record at the close of business on May 7, 2024.

Bristol Myers Squibb Announces New Data from the Long-Term DAYBREAK Study Reinforcing Efficacy and Safety of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis

Retrieved on: 
Thursday, February 29, 2024
Biotechnology, Pharmaceutical, Health, UCSF, Master of Science, BMY, MAS, Research, Doctor of Philosophy, Headache, Month, Upper respiratory tract infection, Treatment, COVID-19, Risk, Common, Bristol Myers Squibb, Multiple sclerosis, Safety, University, Neurology, Disability, Abstract, Patient, Disease, Observational study, Poster, Circulatory system, Pharmaceutical industry

Bristol Myers Squibb (NYSE: BMY) today announced new results from the Phase 3 DAYBREAK open-label extension trial, demonstrating the long-term efficacy and safety profile of Zeposia (ozanimod) in patients with relapsing forms of multiple sclerosis (MS).

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced new results from the Phase 3 DAYBREAK open-label extension trial, demonstrating the long-term efficacy and safety profile of Zeposia (ozanimod) in patients with relapsing forms of multiple sclerosis (MS).
  • In the DAYBREAK long-term extension study, treatment with Zeposia demonstrated a low annualized relapse rate of 0.098.
  • Three- and six-month confirmed disability progression was absent in 82.8% and 84.8% of participants in the trial respectively.
  • No new safety signals emerged; data from this long-term observational study of patients treated for up to 81.5 months were consistent with the established safety profile of Zeposia.

BlossomHill Therapeutics Closes $100 Million Series B Financing

Retrieved on: 
Thursday, February 29, 2024
Research, FDA, Public Relations, Investor Relations, Communications, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, OrbiMed, Autoimmune disease, Intelligence, General partnership, Quality of life, Drug development, Drug design, Bristol Myers Squibb, Therapy, Life expectancy, Medicine, Patient, IND, Cancer, Pharmaceutical industry

BlossomHill Therapeutics, Inc. , a biotechnology company focused on the design and development of small molecule medicines for treating cancer and autoimmune diseases, today announced the closing of a $100 million Series B financing round.

Key Points: 
  • BlossomHill Therapeutics, Inc. , a biotechnology company focused on the design and development of small molecule medicines for treating cancer and autoimmune diseases, today announced the closing of a $100 million Series B financing round.
  • In conjunction with the financing round, Sundeep Agrawal, M.D., General Partner at Colt Ventures, and Timothy Stubbs, M.D., Principal at Vivo Capital, will join the BlossomHill Board of Directors.
  • This financing brings the total capital raised by the company to $173 million.
  • “We appreciate the strong support from our new and existing investors in this round of financing,” said J. Jean Cui, Ph.D., President and Chief Executive Officer of BlossomHill Therapeutics.

Tapestry, Inc. Appoints Kevin Hourican and David Elkins to Board of Directors

Retrieved on: 
Thursday, February 29, 2024
Fashion, Other Retail, Luxury, Retail, Specialty, CFO, Acquisition, Kate Spade, BMY, AstraZeneca, CVS Health, Final good, Senior, Restaurant, Boeing, Multimedia, Pennsylvania State University, Drexel University, SYY, Record, Marketing, Health, Growth, Financial system, University, Business development, Bristol Myers Squibb, BMS, Pharmacy, Executive, Patient, CVS Pharmacy, CVS, Supply chain management, Medical device, Meal, Mid-Atlantic (United States), Management

The appointments of Mr. Hourican and Mr. Elkins to the Board bring the membership to eleven, including ten independent directors.

Key Points: 
  • The appointments of Mr. Hourican and Mr. Elkins to the Board bring the membership to eleven, including ten independent directors.
  • Kevin and David bring significant strategic and financial expertise, with successful track records of delivering innovation and disciplined global growth, including deep M&A experience.
  • Upon his appointment, Kevin Hourican said, "I am excited to be joining the Board of Directors of Tapestry, an innovative, purpose-driven company with a consumer-led approach to building enduring brands.
  • Upon his appointment, David Elkins stated, “I’m honored to join Tapestry’s Board of Directors at this important chapter in the company’s history.

Peter Cuneo Appointed as Chairman of the Board of Directors at OCSiAl

Retrieved on: 
Wednesday, February 28, 2024
Other Energy, Sustainability, Alternative Energy, Energy, Technology, Environment, Other Manufacturing, Nanotechnology, Engineering, Chemicals, Plastics, Other Technology, Manufacturing, Bristol Myers Squibb, The Walt Disney Company, Remington (personal care brand), Marvel Entertainment, Carbon, Black, Management

OCSiAl, the global leader in the industrial synthesis of graphene nanotubes, announces the appointment of Peter Cuneo as Chairman of the Board of Directors.

Key Points: 
  • OCSiAl, the global leader in the industrial synthesis of graphene nanotubes, announces the appointment of Peter Cuneo as Chairman of the Board of Directors.
  • Mr. Cuneo brings to OCSiAl his wealth of strategic leadership experience and a proven track record of investment in many industries.
  • Mr. Cuneo said, “I am thrilled to be joining OCSiAl which has the potential to become a world leader in nanotechnology.”
    Konstantin Notman, CEO of OCSiAl, commented, “I am delighted to welcome Peter to the Board.
  • Collaborating with customers and partners, OCSiAl creates new generations of nano-augmented materials and end products that have previously unattainable properties.

Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates

Retrieved on: 
Tuesday, February 27, 2024
Oncology, Mental Health, Health, Infectious Diseases, Neurology, Pharmaceutical, Biotechnology, NSCLC, TED, Blood pressure, Cervical cancer, Psoriasis, Cetuximab, Infection, New Drug Application, SCLC, MAA, National Medical Products Administration, PMA, CIDP, NTRK, FDA, Nivolumab, Food, GEJ, Shanda, Schizophrenia, PDUFA, CRC, Bristol Myers Squibb, BMS, ADP, Safety, Mirati, TPS, Disease, HKT, Patient, Clinical trial, METIS, Fusion, Pancreatic cancer, NDA, NMPA, Pharmaceutical industry

The New Drug Application (NDA) that Zai Lab submitted to the NMPA for this indication is under priority review.

Key Points: 
  • The New Drug Application (NDA) that Zai Lab submitted to the NMPA for this indication is under priority review.
  • Zai Lab has joined the global Phase 3 FORTITUDE-102 study of bemarituzumab in combination with nivolumab and chemotherapy in first-line gastric or GEJ cancer in Greater China.
  • Zai Lab to submit an sBLA to the NMPA for efgartigimod SC in CIDP in the first half of 2024.
  • Zai Lab to complete patient enrollment in the China bridging study in schizophrenia in the fourth quarter of 2024.

ReNAgade Therapeutics Appoints Joe Bolen, Ph.D., Chief Science Innovation Officer

Retrieved on: 
Tuesday, February 27, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Bangladesh Technical Education Board, Takeda Pharmaceutical Company, MPM, Schering-Plough, Science Publishing Group, Hoechst AG, Research and development, NIH, Moderna, PureTech Health, Drug development, Bristol Myers Squibb, Doctor of Philosophy, Renegade, University, Partner, RNA, Therapy, Patient, Protein, Takeda Oncology, Development, Immune system, Pharmaceutical industry

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Joe Bolen, Ph.D., an Executive Partner at MPM BioImpact, former Chief Scientific Officer at PureTech Health and former President of Research and Development of Moderna Therapeutics, will serve as the company’s first Chief Science Innovation Officer.

Key Points: 
  • ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Joe Bolen, Ph.D., an Executive Partner at MPM BioImpact, former Chief Scientific Officer at PureTech Health and former President of Research and Development of Moderna Therapeutics, will serve as the company’s first Chief Science Innovation Officer.
  • “Joe is a pioneering scientist and drug development expert who brings to ReNAgade more than four decades of experience in oncology and immunology,” said Amit D. Munshi, Chief Executive Officer of ReNAgade.
  • Before joining PureTech, he oversaw all aspects of research and development for Moderna Therapeutics as President of Research & Development and Chief Scientific Officer.
  • Previously, he was Chief Scientific Officer at Millennium Pharmaceuticals and Global Head of Oncology Research at Takeda Pharmaceutical Company.

Bristol Myers Squibb to Participate in the TD Cowen 44th Annual Health Care Conference

Retrieved on: 
Monday, February 26, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Bristol Myers Squibb, BMY, Conference

Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the TD Cowen 44th Annual Health Care Conference in Boston, Massachusetts, on Monday, March 4, 2024.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the TD Cowen 44th Annual Health Care Conference in Boston, Massachusetts, on Monday, March 4, 2024.
  • Roland Chen, M.D., senior vice president, Immunology, Cardiovascular & Neuroscience development, will answer questions about the company during a fireside chat at 9:50 a.m.
  • Investors and the general public are invited to listen to a live webcast of the session here .
  • An archived edition of the session will be available following its conclusion.

Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform

Retrieved on: 
Monday, February 26, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Acquisition, BMY, Covington & Burling, Growth, RPT, Bristol Myers Squibb, Cooley LLP, Patient, SSTR2, BofA Securities, Tax, Eastern Time Zone, LLP, IND, Centerview Partners, Pharmaceutical industry

Bristol Myers Squibb (NYSE: BMY) announced today that it has successfully completed its acquisition of RayzeBio, Inc. (NASDAQ: RYZB).

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) announced today that it has successfully completed its acquisition of RayzeBio, Inc. (NASDAQ: RYZB).
  • With the completion of the acquisition, RayzeBio shares have ceased trading on the NASDAQ Global Market and RayzeBio is now a wholly owned subsidiary of Bristol Myers Squibb.
  • “We are excited to complete this transaction, which adds radiopharmaceutical therapeutics (RPTs), one of the fastest-growing new modalities for treating patients with solid tumors,” said Chris Boerner, Ph.D., Chief Executive Officer, Bristol Myers Squibb.
  • BofA Securities, Inc., is serving as financial advisor to Bristol Myers Squibb, and Covington & Burling LLP is serving as legal counsel.

Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update

Retrieved on: 
Thursday, February 22, 2024
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Acquisition, PANSS, Blood pressure, KRTX, NEI, FDA, Food, Schizophrenia, PDUFA, Psychiatry, Bristol Myers Squibb, Safety, Psychosis, Therapy, Patient, Congress, Positive, NDA, Pharmaceutical industry

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a general business update.

Key Points: 
  • Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a general business update.
  • Results from the EMERGENT-2 trial published in The Lancet in December 2023.
  • Announced positive results from the Phase 1b Ambulatory Blood Pressure Monitoring trial in schizophrenia in the fourth quarter of 2023.
  • Presented additional data from the EMERGENT program at the 2023 Neuroscience Education Institute (NEI) Congress and the CNS Summit in the fourth quarter of 2023.